Tomas Pulido

Tomas Pulido
Instituto Nacional de Cardiología · Clinical Research

MD, Associate Professor of Medicine. Universidad Nacional Autónoma de México
Supervised and look over all the clinical research protocols at my institution. Secretary of the Research Committee

About

173
Publications
21,652
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
7,845
Citations
Citations since 2016
63 Research Items
3811 Citations
20162017201820192020202120220200400600
20162017201820192020202120220200400600
20162017201820192020202120220200400600
20162017201820192020202120220200400600
Introduction
Tomas Pulido currently is deputy director of clinical research at Instituto Nacional de Cardiología. Tomas does research in Pulmonary vascular diseases including pulmonary embolism, pulmonary hypertension and congenital heart disease. Their most recent publication is 'Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.'
Additional affiliations
May 2000 - April 2019
Instituto Nacional de Cardiología
Position
  • Head of Department
January 2000 - April 2013
Education
July 1997 - June 1999
University of Manitoba
Field of study
  • Respiratory Medicine
March 1995 - February 1997
Instituto Nacional de Cardiología
Field of study
  • Cardiopulmonary Medicine
March 1992 - February 1995
Centro Médico ABC
Field of study
  • Internal Medicine

Publications

Publications (173)
Article
Full-text available
Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT‐CHILD (NCT02562235), a multicenter, single‐arm, 24‐week, open‐label, phase 3 study. Patient...
Article
Full-text available
Introduction: In SERAPHIN, a long-term, event-driven, double-blind randomised controlled trial in pulmonary arterial hypertension (PAH), macitentan 10 mg significantly reduced the risk of morbidity/mortality compared with placebo. Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in...
Article
Full-text available
Pulmonary arterial hypertension (PAH) is a severe clinical condition that significantly affects patients’ quality of life and survival. Since the emergence of prostanoids 45 years ago, different drugs acting on vasoconstriction/vasodilation mechanisms have been developed for the treatment of PAH. Current evidence shows that better results occur whe...
Preprint
Pulmonary arterial hypertension (PAH) is a severe clinical condition that significantly affects patients’ quality of life and survival. Since the emergence of prostanoids 45 years ago, different drugs acting on vasoconstriction/vasodilation mechanisms have been de- veloped for the treatment of PAH. Current evidence shows that better results occur w...
Article
Full-text available
Oral treprostinil has been shown to improve exercise capacity and delay disease progression in patients with pulmonary arterial hypertension (PAH), but its effects on hemodynamics are not well-characterized. The FREEDOM-EV trial was a Phase III, international, placebo-controlled, double-blind, event-driven study in 690 participants with PAH who wer...
Article
Full-text available
Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regards to disease etiology, health insurance coverage and drug availability. A group of experts from Latin America, met to share regional experiences and propose possible lines of collaboration. The avail...
Conference Paper
Full-text available
Background: Pulmonary arterial hypertension (PAH) in children is a rare condition with substantial morbidity and mortality. Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with PAH. Aim: PATENT-CHILD evaluated the safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with...
Article
Background Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of r...
Article
Pulmonary arterial hypertension (PAH) is an uncommon but lethal and progressive disease in which prostacyclin, nitric oxide and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Endothelin receptor antagonists are a class of drugs that have been approved as PAH therapy. Macitentan is a lipophilic, tissue spe...
Article
Background In animal models of pulmonary arterial hypertension (PAH), angiotensin converting enzyme type 2 (ACE2) and Angiotensin 1–7 [Ang-(1–7)] have been shown to have vasodilatory, anti-proliferative, anti-fibrotic and anti-hypertrophic properties. However, the status and role of the ACE2-Ang-(1–7) axis in human PAH is incompletely understood....
Article
Full-text available
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown. Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral...
Article
Full-text available
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral...
Article
Full-text available
Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) randomized controll...
Article
Purpose Oral treprostinil (TRE) has been shown to improve exercise capacity in patients with pulmonary arterial hypertension (PAH), but its effect on clinical outcomes was unknown. Methods In this global, event-driven study, eligible participants taking one approved PAH medication were randomized to TRE or placebo (PBO). Dosing was individualized...
Article
Full-text available
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the developmen...
Article
Purpose of review: The purpose of this review is to demonstrate advances in the medical treatment of pulmonary arterial hypertension (PAH). Reviewed will be the evidence that favors the use of risk assessment in the treatment of PAH. Optimization of combination therapy depending on the risk or worsening will be reviewed. Finally, recent advances i...
Article
Full-text available
Background Eisenmenger syndrome describes congenital heart disease-associated severe pulmonary hypertension accompanied by right-to-left shunting. The multicenter, double-blind, randomized, placebo-controlled, 16-week, phase III MAESTRO study (Macitentan in Eisenmenger Syndrome to Restore Exercise Capacity) evaluated the efficacy and safety of the...
Article
Full-text available
Background: Pulmonary arterial hypertension (PAH) is a fatal complication in patients with connective tissue disease (CTD). Objective: The objective of the study was to study the prognostic value of the acute pulmonary vasoreactivity test with inhaled iloprost and its association with clinical deterioration in a tertiary care academic medical ce...
Article
Full-text available
Background: Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of 380-440 m may have improved prognosis. Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk distance and long-term outcomes was explored. Methods: Patients with...
Data
List of ethics committee/institutional review board(s) that approved the study. (DOCX)
Data
Hazard of PAH-related death or hospitalization and all-cause death events using 6MWD as a continuous parameter. (DOCX)
Article
Background: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials. Objectives: The purpose of these analyses was to assess the impact of morbidity events on...
Article
Full-text available
Background: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patie...
Article
Full-text available
SERAPHIN was a double-blind, placebo-controlled, event-driven phase III trial that evaluated the effects of long-term treatment with macitentan, an oral endothelin receptor antagonist, in patients with pulmonary arterial hypertension (PAH). The majority of patients were receiving PAH therapy at enrollment, providing the opportunity to evaluate the...
Article
Full-text available
Objetivo: La hipertensión arterial pulmonar (HAP) es una enfermedad progresiva que involucra diversas vías patológicas y mediadores inflamatorios. El ancho de distribución eritrocitaria (ADE) es un biomarcador de bajo costo asociado a inflamación crónica y predictor independiente de mal pronóstico de enfermedades cardiovasculares. Los objetivos del...
Article
Aims: The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary endpoint (time to first morbidity/mortality event), was explored. Methods and results: Of the 7...
Article
Full-text available
Background: Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The a...
Article
Full-text available
Considerando el impacto en términos de morbilidad y mortalidad de los tres síndromes vasculares agudos, las presentes guías y recomendaciones para el uso de trombolisis y anticoagulación tienen como principal objetivo ofrecer a todos los médicos interesados recomendaciones apoyadas en los mejores y más actuales niveles de evidencia. Para tal fin, s...
Article
Full-text available
Objective: REMEHIP is a prospective, multicentre registry on pulmonary hypertension. The main objective will be to identify the clinical profile, medical care, therapeutic trends and outcomes in adult and pediatric Mexican patients with well-characterized pulmonary hypertension. Methods: REMEHIP a multicenter registry began in 2015 with a planne...
Article
Full-text available
Chronic thromboembolic pulmonary hypertension (CTEPH) represents a unique subtype of pulmonary hypertension characterized by the presence of mechanical obstruction of the major pulmonary vessels caused by venous thromboembolism. CTEPH is a progressive and devastating disease if not treated, and is the only subset of PH potentially curable by a surg...
Article
Acute pulmonary embolism is one of the main causes of death, morbidity and hospitalisation [1, 2]. The most common cause of early death in these patients is right ventricular failure [1–3]. Complete resolution of the pulmonary thrombus at 6 months of evolution is not achieved in 57% of patients, with persistent right ventricular dysfunction (RVD) i...
Article
Full-text available
Despite advances in pharmacologic treatment, pulmonary arterial hypertension (PAH) remains a fatal disease. In recent years, surgical/interventional approaches including balloon dilation atrial septostomy and Potts anastomosis have been applied to improve the hemodynamic variables associated with right ventricular failure in the setting of PAH. The...
Article
Full-text available
Pulmonary Arterial hypertension (PAH) is a chronic and progressive disease characterized by an increase in pulmonary vascular resistance due to severe remodeling of the small pulmonary arteries. In PAH, the endothelial cells fail to maintain their homeostatic balance, with the consequent impaired production of vasodilators and over-expression of va...
Article
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening disease. We investigated associations between markers of disease severity and long-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy (PEA) who were receiving...
Article
Full-text available
In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts. Patients allocated to...
Article
Pulmonary arterial hypertension (PAH) is a progressive fatal disease. Variable response and tolerability to PAH therapeutics suggests that genetic differences may influence outcomes. The endothelin pathway is central to pulmonary vascular function, and several polymorphisms and/or mutations in the genes coding for endothelin-1 (ET-1) and its recept...
Article
Full-text available
In experimental and clinical cardiology, phosphodiesterase type 5 (PDE-5) inhibitors have brought scientific interest as a therapeutic tool in pulmonary arterial hypertension (PAH) management in recent years. Phosphodiesterases are a superfamily of enzymes that inactivate cyclic adenosine monophosphate and cyclic guanosine monophosphate, the second...
Article
Full-text available
Despite significant advances in pharmacological treatments, pulmonary arterial hypertension remains an incurable disease with an unreasonably high morbidity and mortality. Although specific pharmacotherapies have shifted the survival curves of patients and improved exercise endurance as well as quality of life, it is also true that these pharmacolo...